Gazi University
Ankara, Turkey (Türkiye)
NCT Number: NCT05970939
Neurological diseases are central nervous system diseases that cause an increase in the level of disability and limitations in daily life. Multiple Sclerosis (MS), stroke, and Parkinson's Disease (PD) are among the most common apparent neurological diseases, and epidemiological studies show that their prevalence has increased over time worldwide. Although MS, stroke, and PD have different causes and neurological aspects, they generally cause motor, sensory, and/or cognitive impairments, leading to restriction of the individual's activities and participation. Today, physiotherapy and rehabilitation approaches together with optimal medical and surgical treatment are the cornerstones of treatment for these diseases. Recently, it has been stated that various telerehabilitation interventions in the field of physiotherapy and rehabilitation may be an additional option to the rehabilitation approaches applied in the clinic. On the other hand, It is important to evaluate the level of usability in expanding the usability of telerehabilitation services and determining the best telerehabilitation service. For this reason, there is a need for questionnaires investigating the satisfaction level of physiotherapy and rehabilitation applied through telerehabilitation.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Ankara, Turkey (Türkiye)
Questionnaire items will be created in two stages. First, 5 experts will independently review the literature on "telerehabilitation" and "usability". In addition, these experts will be asked to create a pool of questions based on their experiences in telerehabilitation and by taking the opinions of patients receiving telerehabilitation about usability. Then, 5 experts will come together and obtain a single question pool containing the questions they deem important in their question pool. The second step will involve scaling the elements. In this study, scale items will be scored on a five-point Likert scale, ranging from 1, strongly disagree to 5, strongly agree. Then, it will be applied to a pilot group of 10 people and it will be evaluated whether the items prepared by the experts are understood by the patients. In line with the expert opinion and the result of the pilot study, the final version of the scale will be decided and applied to MS, PD, and stroke patients who make up the study group. Finally, the validity and reliability of the questionnaire will be calculated.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
This study will be examined the development, validity, and reliability of the Telerehabilitation Usability Questionnaire in patients with MS.
Time frame: Baseline
Patients get a minimum of 0 points (best condition) and a maximum of 4 points (worst condition) for each question on this scale
Time frame: he second assessment will be conducted after the one week
Patients get a minimum of 0 points (best condition) and a maximum of 4 points (worst condition) for each question on this scale
Gazi University
Other
Development, Reliability and Validity of the Telerehabilitation Usability Questionnaire- TrUQ in Neurological Diseases
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05520554
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Ankara, Turkey (Türkiye)
View Trial DetailsNCT05575674
Brachial Plexus Injury, Brain Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05536921
Brain Damage, Chronic, Brain Diseases
Częstochowa, Poland
View Trial DetailsNCT06235580
Autoimmune Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Paris, Île-de-France Region, France
View Trial Details